Foresite Capital Management VI’s RAPT Therapeutics RAPT Stock Holding History

Foresite Capital Management VI’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,562,500	Closed	-$52.9M	–	19
2025 Q4	$52.9M	Hold	1,562,500	–	–	16%	2
2025 Q3	$40.3M	Hold	1,562,500	–	–	15.57%	2
2025 Q2	$12.5M	Hold	1,562,500	–	–	7.03%	5
2025 Q1	$15.3M	Hold	1,562,500	–	–	8.35%	4
2024 Q4	$19.8M	Buy	+1,562,500	New	+$19.8M	8.8%	4

Foresite Capital Management VI's RAPT Position: Q1 2026 in Review

Foresite Capital Management VI sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 1,562,500 shares — an estimated $52.9M sold.

Foresite Capital Management VI first reported a position in RAPT in Q4 2024 and held it in 5 quarters. The position peaked at $52.9M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Foresite Capital Management VI reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Foresite Capital Management VI sold 1,562,500 RAPT Therapeutics shares in Q1 2026, an estimated $52.9M.
Foresite Capital Management VI first reported a position in RAPT Therapeutics in Q4 2024 and held it in 5 quarters.
Foresite Capital Management VI's RAPT Therapeutics position peaked at $52.9M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Foresite Capital Management VI's 13F filing for Q1 2026, filed 15 May 2026.